Pharmaceuticals company Ajanta Pharma announced Q3FY25 results Revenue from operations at Rs 1,146 crore against Rs 1,105 crore; up 4%. EBITDA at Rs 321 crore against Rs 314 crore; up 2%; EBITDA at 28%. Profit after tax at Rs 233 crore against Rs 210 crore; up 11%; PAT at 20%. Result PDF
Pharmaceuticals company Ajanta Pharma announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Revenue from operations at Rs 1,187 crore against Rs 1,028 crore; up 15%. EBITDA at Rs 311 crore against Rs 291 crore; up 7%; EBITDA at 26%. Profit after tax at Rs 216 crore against Rs 195 crore; up 11%; PAT at 18%. H1FY25 Financial Highlights: Revenue from operations at Rs 2,332 crore against Rs 2,049 crore; up 14%. EBITDA at Rs 642 crore against Rs 572 crore; up 12%; EBITDA at 28%. Profit after tax at Rs 462 crore against Rs 403 crore; up 15%; PAT at 20%. Cashflow from operations (CFO) was Rs 776 crore, EBITDA to CFO conversion of 121%. Free cashflow (FCF) was Rs 322 crore, FCF to PAT conversion of 70%. ROCE stood at a healthy level of 34% and RONW at 26%. Result PDF